Literature DB >> 26918298

Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012.

Daniela Danneman1, Linda Drevin2, Brett Delahunt3, Hemamali Samaratunga4,5, David Robinson6, Ola Bratt7,8, Stacy Loeb9, Pär Stattin10,11, Lars Egevad1,12.   

Abstract

OBJECTIVES: To investigate how well the Gleason score in diagnostic needle biopsies predicted the Gleason score in a subsequent radical prostatectomy (RP) specimen before and after the 2005 International Society of Urological Pathology (ISUP) revision of Gleason grading, and if the recently proposed ISUP grades 1-5 (corresponding to Gleason scores 6, 3 + 4, 4 + 3, 8 and 9-10) better predict the RP grade. PATIENTS AND METHODS: All prostate cancers diagnosed in Sweden are reported to the National Prostate Cancer Register (NPCR). We analysed the Gleason scores and ISUP grades from the diagnostic biopsies and the RP specimens in 15 598 men in the NPCR who: were diagnosed between 2000 and 2012 with clinical stage T1-2 M0/X prostate cancer on needle biopsy; were aged ≤70 years; had serum PSA concentration of <20 ng/mL; and underwent a RP <6 months after diagnosis as their primary treatment.
RESULTS: Prediction of RP Gleason score increased from 55 to 68% between 2000 and 2012. Most of the increase occurred before 2005 (nine percentage points; P < 0.001); however, when adjusting for Gleason score and year of diagnosis in a multivariable analysis, the prediction of RP Gleason score decreased over time (odds ratio [OR] 0.98; P < 0.002). A change in the ISUP grades would have led to a decreasing agreement between biopsy and RP grades over time, from 68% in 2000 to 57% in 2012, with an OR of 0.95 in multivariable analysis (P < 0.001).
CONCLUSION: Agreement between biopsy and RP Gleason score improved from 2000 to 2012, with most of the improvement occurring before the 2005 ISUP grading revision. Had ISUP grades been used instead of Gleason score, the agreement between biopsy and RP grade would have decreased, probably because of its separation of Gleason score 7 into ISUP grades 2 and 3 (Gleason score 3 + 4 vs 4 + 3).
© 2016 The Authors BJU International © 2016 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #PCSM; #ProstateCancer; Gleason grade; needle biopsy; pathology; prostate cancer

Mesh:

Year:  2016        PMID: 26918298     DOI: 10.1111/bju.13458

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  9 in total

Review 1.  Molecular correlates of intermediate- and high-risk localized prostate cancer.

Authors:  Huihui Ye; Adam G Sowalsky
Journal:  Urol Oncol       Date:  2018-03-02       Impact factor: 3.498

2.  Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations.

Authors:  Ahmed Hussein Zedan; Søren Garm Blavnsfeldt; Torben Frøstrup Hansen; Boye Schnack Nielsen; Niels Marcussen; Mindaugas Pleckaitis; Palle Jörn Sloth Osther; Flemming Brandt Sørensen
Journal:  PLoS One       Date:  2017-06-19       Impact factor: 3.240

3.  Risk of upgrading from prostate biopsy to radical prostatectomy pathology: Is magnetic resonance imaging-guided biopsy more accurate?

Authors:  Ning Xu; Yu-Peng Wu; Xiao-Dong Li; Min-Yi Lin; Qing-Shui Zheng; Shao-Hao Chen; Jun-Feng Li; Yong Wei; Xue-Yi Xue
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

Review 4.  Old men with prostate cancer have higher risk of Gleason score upgrading and pathological upstaging after initial diagnosis: a systematic review and meta-analysis.

Authors:  Xiaochuan Wang; Yu Zhang; Zhengguo Ji; Peiqian Yang; Ye Tian
Journal:  World J Surg Oncol       Date:  2021-01-20       Impact factor: 2.754

Review 5.  Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer.

Authors:  Wietske I Luining; Matthijs C F Cysouw; Dennie Meijer; N Harry Hendrikse; Ronald Boellaard; André N Vis; Daniela E Oprea-Lager
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

6.  The impact of the 2005 International Society of Urological Pathology Gleason grading consensus on active surveillance for prostate cancer.

Authors:  Venkat M Ramakrishnan; Karolin Bossert; Gad Singer; Kurt Lehmann; Lukas J Hefermehl
Journal:  Cent European J Urol       Date:  2017-10-20

7.  Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry.

Authors:  Nicholas Bullock; Andrew Simpkin; Sarah Fowler; Murali Varma; Howard Kynaston; Krishna Narahari
Journal:  BMC Urol       Date:  2019-10-17       Impact factor: 2.264

8.  Prostate cancer grading, time to go back to the future.

Authors:  Lars Egevad; Brett Delahunt; David G Bostwick; Liang Cheng; Andrew J Evans; Troy Gianduzzo; Markus Graefen; Jonas Hugosson; James G Kench; Katia R M Leite; Jon Oxley; Guido Sauter; John R Srigley; Pär Stattin; Toyonori Tsuzuki; John Yaxley; Hemamali Samaratunga
Journal:  BJU Int       Date:  2020-11-27       Impact factor: 5.588

9.  Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer.

Authors:  Matthijs C F Cysouw; Bernard H E Jansen; Tim van de Brug; Daniela E Oprea-Lager; Elisabeth Pfaehler; Bart M de Vries; Reindert J A van Moorselaar; Otto S Hoekstra; André N Vis; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-07-31       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.